494 related articles for article (PubMed ID: 14767273)
1. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.
Flanigan RC; Mickisch G; Sylvester R; Tangen C; Van Poppel H; Crawford ED
J Urol; 2004 Mar; 171(3):1071-6. PubMed ID: 14767273
[TBL] [Abstract][Full Text] [Related]
2. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Flanigan RC; Salmon SE; Blumenstein BA; Bearman SI; Roy V; McGrath PC; Caton JR; Munshi N; Crawford ED
N Engl J Med; 2001 Dec; 345(23):1655-9. PubMed ID: 11759643
[TBL] [Abstract][Full Text] [Related]
3. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in metastatic renal cancer.
Flanigan RC
Curr Urol Rep; 2003 Feb; 4(1):36-40. PubMed ID: 12537937
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy: past, present and future.
Galazi M; Rodriguez-Vida A; Josephides E; Chau NM; Chowdhury S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):271-7. PubMed ID: 24392671
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
7. Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ.
Shinohara N; Abe T; Sazawa A; Maruyama S; Shindo J; Sato S; Suzuki S; Nonomura K
Jpn J Clin Oncol; 2012 Feb; 42(2):113-9. PubMed ID: 22131341
[TBL] [Abstract][Full Text] [Related]
8. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
[TBL] [Abstract][Full Text] [Related]
9. Commentary on "cytoreduction nephrectomy in metastatic renal cancer: the results of Southwest Oncology Group Trial 8949".
Tannock IF
J Clin Oncol; 2000 Nov; 18(21 Suppl):39S-42S. PubMed ID: 11060324
[No Abstract] [Full Text] [Related]
10. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
11. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
14. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
16. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
17. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Healy KA; Marshall FF; Ogan K
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1295-304. PubMed ID: 16925495
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer?
Bromwich E; Hendry D; Aitchison M
BJU Int; 2002 Apr; 89(6):523-5. PubMed ID: 11942956
[TBL] [Abstract][Full Text] [Related]
20. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
Karam JA; Wood CG
Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]